LY294002

For research use only.

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

1343 publications

LY294002 Chemical Structure

CAS No. 154447-36-6

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's LY294002 has been cited by 1343 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Targets
CK2 [5]
(Cell-free assay)		 p110α [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 p110β [1]
(Cell-free assay)		 DNA-PK [6]
(Cell-free)
98 nM 0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells NHjzU3NHfW6ldHnvckBie3OjeR?= MoC4TY5pcWKrdHnvckBw\iCKaYOteIFo\2WmIHLveolv\SCSSUPLJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVA:OTBizszNMi=> M4PaelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOUm4N|UyLz5zMEm5PFM2OTxxYU6=
HeLa cells NG\GZ|FDcW6maX7nJIFn\mmwaYT5JIF{e2G7 NIrQbldDcW6maX7nJIFn\mmwaYT5JIZweiCSSUOtb4lv[XOnIHnzc4xifGWmIH\yc40hUGWOYTDj[YxteyxiS3m9OkDPxE1? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
HeLa cells NHPQdGVHfW6ldHnvckBie3OjeR?= NWm5cIhsUW6qaXLpeIlwdiCxZjDtWG9TKHC{b4TlbY4hcXOxbHH0[YQh\nKxbTDI[WxiKGOnbHzzMEBKSzVyPUKuOUDPxE1w Mn:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O|AoRjF3NkW4PFcxRC:jPh?=
HeLa (human carcinoma) cells. NYK5R|U2TnWwY4Tpc44h[XO|YYm= Mn[4TY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NCCLQ{WwQVEvPCEQvF2u M3LIV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
human PC3 cells MoHwVJJwdGmoZYLheIlwdiCjc4PhfS=> M1GxbVI2KM7:TR?= M3L3PFEzOCCq NUW1eWN3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZQhOjVidV2gZYZ1\XJiMUKwJIhzeyCkeTDNWHQh[XO|YYmgdoVt[XSrdnWgeI8hTE2VTx?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjZ6MEG1PUc,OTZ4OECxOVk9N2F-
human BJ cells MnzZSpVv[3Srb36gZZN{[Xl? M{LIdVI2KM7:TR?= MlrDNkBp MWnBZ5RqfmG2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25iYYSgWIhzOzB6IHnuJHBFT0Zvc4TpcZVt[XSnZDDz[ZJ2dSC|dHHyeoVlKGi3bXHuJGJLKGOnbHzzJIF1KDJ3IIXNJJRz\WG2ZXSgNkBpenNiYnXmc5JmKFCGR1[gZ4hidGynbnflJIJ6KGmvbYXuc4Jtd3S2aX7n NXW1VWF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3OlcxQDVpPkG2O|Y4ODh3PD;hQi=>
human BJ cells MV\GeY5kfGmxbjDhd5NigQ>? M4XJW|I2KM7:TR?= NX23WG1kOiCq NU\WSWhVUW6qaXLpeIlwdiCxZjDQTVNMKHOrZ37hcIlv\yCrbjDQSGdHNXO2aX31cIF1\WRic3XyeY0he3Sjco\l[EBpfW2jbjDCTkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDsZZNucWRiRVfGVE9RUCCmb33hbY4hd2ZiQXv0JIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHBJNUWJRmCgdoVlcXO2cnnieZRqd25idH:gdIxie22jIH3lcYJz[W6nIHH0JFI2KHWPIITy[YF1\WRiMjDodpMh[mWob4LlJHBFT0ZiY3jhcIxmdmenIHL5JINwdm[xY3HsJI1q[3Kxc3PvdJk> M4f3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O|A5PTxxYU6=
mouse mast cells NHjteYlHfW6ldHnvckBie3OjeR?= NWHWeWJWOjBizszN M{P3SmlvcGmkaYTpc44hd2ZiU1PGMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gcY92e2VibXHzeEBk\WyuczDheEAzOCEQvF2= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
THP1 cells M2WwXmZ2dmO2aX;uJIF{e2G7 M2HLd2lvcGmkaYTpc44hd2ZiTVPQNU1qdmS3Y3XkJINp\W2xdHH4bZMhd2ZiVFjQNUBk\WyuczygTWM2OD1|NzFOwG0v NUXWbFlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O|g6PzR{PD;hQi=>
mouse Raw264 macrophage MVfGeY5kfGmxbjDhd5NigQ>? Ml75TY5pcWKrdHnvckBw\iCFNXGtcYVlcWG2ZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gcY92e2ViUnH3NlY1KG2jY4LvdIhi\2VuIFnDOVA:OTBizszNMi=> NFjBWnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke4PVc1Oid-MU[3PFk4PDJ:L3G+
THP1 cells NUi0PFFrTnWwY4Tpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKE2FUEGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuOlUh|ryPLh?= Mk\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O|QzRC:jPh?=
THP1 cells MVHGeY5kfGmxbjDhd5NigQ>? MlzMTY5pcWKrdHnvckBw\iCVQ1[xMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlAyKM7:TT6= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
human A375 cells M3LTeHBzd2yrZnXyZZRqd25iYYPzZZk> MoP3OFYhcA>? NH6xXGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOgZYZ1\XJiNE[gbJJ{NCCLQ{WwQVgvPCEQvF2u MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzB2OUK0PEc,OTdyNEmyOFg9N2F-
HeLa cells M1rMSmZ2dmO2aX;uJIF{e2G7 M1S5RmlvcGmkaYTpc44hd2ZiQWitO|UxOyCkaX7kbY5oKHSxIILlZ49u[mmwYX70JHBtczNiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[nliV3XzeIVzdiCkbH;0MEBKSzV;MzFOwG0v MnSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzM{WyOFgoRjF5MUO1NlQ5RC:jPh?=
human SW480 cells M1OwPWZ2dmO2aX;uJIF{e2G7 NIfHeIEzOCEQvF2= NY\rZ4ZWOjRiaB?= MYnE[YNz\WG|ZTDpckB{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHj1cYFvKFOZNEiwJINmdGy|IHH0JFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| MmTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2N{K5OlIoRjF5NEeyPVYzRC:jPh?=
human A375 cells MmfFVJJwdGmoZYLheIlwdiCjc4PhfS=> M125PGlvcGmkaYTpc44hd2Zic3XyeY0ucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJIh2dWGwIFGzO|Uh[2WubIOsJGlEPTB;OD60JO69VS5? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMUezPUc,OTd4MEG3N|k9N2F-
human A2780 cells MkjPRZBweHSxc3nzJIF{e2G7 Ml33NkDPxE1? Mnz6NVIhcA>? M3LtPWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gZ4l{eGyjdHnuMZJme2m|dHHueEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDa4SgcIV3\WxiYYSgNkB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqey5? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6NECxPEc,OTd4OESwNVg9N2F-
human H4 cells MWPGeY5kfGmxbjDhd5NigQ>? NUTLeYlQOiCq M2Hv[2Rm[3KnYYPlJIlvKE[\VlWtVmZRMyC4ZYPpZ4xmKGmwdHXud4l1gSCyZYKgZ4VtdCCrbjDoeY1idiCKNDDj[YxteyCjZoTldkAzKGi{czDy[YxifGm4ZTD0c{Bkd262cn;s MorvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyMkS1PFQoRjF6MEK0OVg1RC:jPh?=
Sf9 cells NUXDVHNlTnWwY4Tpc44h[XO|YYm= M1HxPGlvcGmkaYTpc44hd2ZiQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVA:Pi57IN88UU4> NXi1[GRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNlE4OTZpPkG4N|IyPzF4PD;hQi=>
rat RBL2H3 cells Mo[wSpVv[3Srb36gZZN{[Xl? Mn3NTY5pcWKrdHnvckBw\iCDMkOxPFcucW6mdXPl[EBl\We{YX71cIF1cW:wIHnuJJJifCCUQlyyTFMh[2WubIO= NEDxPW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyPFcyPid-MUizNlg4OTZ:L3G+
human U87MG cells MW\GeY5kfGmxbjDhd5NigQ>? MnrWTY5pcWKrdHnvckBw\iCJU1uzMYJmfGFiaX6gbJVu[W5iVUi3UWch[2WubIOgZpkhTUyLU1GsJGlEPTB;OD6xJO69VS5? NWTpO491RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOFU3ODlpPkG4N|Q2PjB7PD;hQi=>
human H460 cells NY\nN4NGTnWwY4Tpc44h[XO|YYm= Mm\VN|Ah|ryP MnHaTY5pcWKrdHnvckBw\iCSSUPLJIlvKGi3bXHuJGg1PjBiY3XscJMh[XO|ZYPz[YQh[XNiQXv0JJBpd3OyaH;yfYxifGmxbjDheEBU\XJiNEezJJVxKHSxIEOwJJVO MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEG2NFEoRjF6NUCxOlAyRC:jPh?=
human U251HRE cells NU\w[IpPTnWwY4Tpc44h[XO|YYm= NEC0bVBKdmirYnn0bY9vKG:oIHj5dI95cWFvaX7keYNm\CCKSV[xJIFkfGm4YYTpc44hcW5iaIXtZY4hXTJ3MVjSSUBk\WyuczDifUBk\WyuIHLhd4VlKHKncH;yeIVzKGenbnWgZZN{[Xl? MnTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEG2NFEoRjF6NUCxOlAyRC:jPh?=
human 184B5 cells M3rudGN6fG:2b4jpZ:Kh[XO|YYm= Ml75R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVg1SjViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTN7LkO3JO69VS5? NWP4RXdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-468 cells M4m5UGN6fG:2b4jpZ:Kh[XO|YYm= NYHYNmtVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:OTBwNDFOwG0v M13neVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-468 cells NIDu[IZEgXSxdH;4bYPDqGG|c3H5 NWLLXnZ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9PE4zKM7:TT6= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
MDA-MB-231 cells NWTZU3o3S3m2b4TvfIlkyqCjc4PhfS=> NU[4UHFVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Pi55MTFOwG0v MnLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-468 cells NHn6cJFEgXSxdH;4bYPDqGG|c3H5 MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3Ojef-8kEBKSzVyPUSuO|Yh|ryPLh?= NV3zT4Z1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells MoXGR5l1d3SxeHnjxsBie3OjeR?= MnXDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpckBxemW|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKPTB;ND6zOUDPxE1w M1vVWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-231 cells NI\HS2dEgXSxdH;4bYPDqGG|c3H5 NXj0VWxvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEDPxE1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSU2zMlMzKM7:TT6= M2fxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells MoDRR5l1d3SxeHnjxsBie3OjeR?= M3vT[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[nliU2LCJIF{e2G7LDDHTV0{NjF4IN88UU4> NUnLWZZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells NH;TTY5EgXSxdH;4bYPDqGG|c3H5 NFPPNnhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFExKHWPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0{NjB6IN88UU4> M4f4dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells NXnydHhNS3m2b4TvfIlkyqCjc4PhfS=> NH7RSolEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFIxKM7:TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oi54MzFOwG0v MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
Sf21 cells MmPZSpVv[3Srb36gZZN{[Xl? MnfqTY5pcWKrdHnvckBw\iCvb4Xz[UBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoMkGgZ4VtdHNuIFnDOVA:OC53IN88UU4> NV;6NpdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
Sf9 cells NHHHSHlndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? M{fEe2lvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3fhcY1iKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7 M2LvPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUKxOlMyLz5{MUGyNVY{OTxxYU6=
Sf9 cells NInoVZNHdHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? M2DhbGlvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3HsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7LDDJR|UxRTBwNUWg{txONg>? NHfu[Ws9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGyNVY{OSd-MkGxNlE3OzF:L3G+
human IGROV1 cells MmjZSpVv[3Srb36gZZN{[Xl? NF\LWXAzPCCq NHrXNYJE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBKT1KRVkGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFexJJBp[XOnIHH0JFUh\m:uZDDJR|UxKGGodHXyJFI1KGi{czDifUBndG:5IHP5eI9u\XS{eR?= Mme2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells NWfRT2JvTnWwY4Tpc44h[XO|YYm= MoC1NlQhcA>? NGXQSIdE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBKT1KRVkGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFexJJBp[XOnIHH0JFEh\m:uZDDJR|UxKGGodHXyJFI1KGi{czDifUBndG:5IHP5eI9u\XS{eR?= NXrBVm5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human IGROV1 cells NGDRc4ZHfW6ldHnvckBie3OjeR?= MWOyOE81QCCq MkHBTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY4njcIlvKERzIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human IGROV1 cells M{PlOGZ2dmO2aX;uJIF{e2G7 NYriU4xJOjRxNEigbC=> NXvMd2FbUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiQVvUJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human HCT116 cells NWjpUVhiS3m2b4TvfIlkyqCjc4PhfS=> Mmm5O|IhcA>? MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Ok4xOSEQvF2u NHfheno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0OVI2OCd-MkG5OFUzPTB:L3G+
human KB cells NFHLUoVEgXSxdH;4bYPDqGG|c3H5 MmLlO|IhcA>? NYC0Ro86S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20OE44PiEQvF2u Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEWyOVAoRjJzOUS1NlUxRC:jPh?=
HUVEC MX7GeY5kfGmxbjDhd5NigQ>? NFvHVVAyOC1{NTFOwG0> NX7RTW43OzBibXnu NFvEOW9KdmirYnn0bY9vKG:oIGTOSoFteGijLYP0bY12dGG2ZXSgbJVu[W5iSVPBUU0yKHC{b33veIVzKGGldHn2bZR6KGW6cILld5Nm\CCrbjDIWXZGSyCjc4Pld5Nm\CCjczDi[ZRiNWejbHHjeI9{cWSjc3WgZYN1cX[rdImgZZQhOTBidH:gNlUhfU1icILleJJm[XSnZDDmc5IhOzBibXnud{Bj\W[xcnWgWG5H[WyyaHGgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> M2SwdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK2OFExLz5{MkCyOlQyODxxYU6=
HUVEC NHvleYdHfW6ldHnvckBie3OjeR?= MljLNVAuOjVizszN NVzzOpRrOTZiaB?= NY[wcmNpUW6qaXLpeIlwdiCxZjDUUmZidHCqYT3zeIlufWyjdHXkJGlESU1vMTDtVm5CKGW6cILld5Nqd25iaX6gTHVXTUNiYYSgNVAhfG9iMkWgeW0heHKndILlZZRm\CCob4KgNVYhcHK|IHLl[o9z\SCWTl\hcJBp[SClaHHscIVv\2VibXXhd5Vz\WRiYX\0[ZIhPiCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nz MmezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMk[0NVAoRjJ{MEK2OFExRC:jPh?=
human HCT116 cells Mm\HSpVv[3Srb36gZZN{[Xl? M{XHd|ExKM7:TR?= NFrne|lKdmirYnn0bY9vKG:oIFHreEBmgHC{ZYPzbY9vKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDheEAyOCC3TTDifUBqdW23bn;icI91KGGwYXz5d4l{ NUnqO2x5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells MVrGeY5kfGmxbjDhd5NigQ>? M1uyeVExKM7:TR?= NGnmN2hKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDINVA1P1JibYX0ZY51KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHH0JFExKHWPIHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> MlmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells NX;QfJBDTnWwY4Tpc44h[XO|YYm= MVqxNEDPxE1? NVrPTW5mUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSWu2IGPldlQ4OyCyaH;zdIhwenmuYYTpc44h[XRiMUCgeW0h[nliaX3teY5w[myxdDDhcoFtgXOrcx?= M2j2d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells NIe5N21HfW6ldHnvckBie3OjeR?= NHTPPZoyOCEQvF2= MWexNEBucW5? NWK1fXk4UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgTFExPDeUIH31eIFvfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells MXrGeY5kfGmxbjDhd5NigQ>? MY[xNEDPxE1? NHXPV5EyOCCvaX6= Mn\ZTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJJV{cW6pIGuzNnBeSVSSIHH0JFExKHWPIHHmeIVzKDFyIH3pcpM> NVLobZdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells M4PSZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm[2OFghcA>? MX7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Nj63JO69VS5? M2i4V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells NWjaSod4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjxT481QCCq NVrQ[GZmT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS56IN88UU4> NXvObVgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NULrVVNbPDhiaB?= MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJGgyODR5UjDteZRidnRiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02NjNizszN MmL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human A549 cells MXjDfZRwfG:6aXRCpIF{e2G7 MV:3NkBp M3HFWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfS=> M4LPXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
human PC3 cells MYDDfZRwfG:6aXRCpIF{e2G7 MoXrO|IhcA>? NXHvS3BsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OlEvOzVizszNMi=> Mnz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEC4OVEoRjJ{NEiwPFUyRC:jPh?=
human HL60 cells M1vjV2N6fG:2b4jpZ:Kh[XO|YYm= NG\0NmM4OiCq MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT65OEDPxE1w MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6MEi1NUc,OjJ2OEC4OVE9N2F-
Sf21 cells MVLGeY5kfGmxbjDhd5NigQ>? NHvqVFJKdmirYnn0bY9vKG:oIH3veZNmKHerbHSgeJlx\SCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnOjFiY3XscJMh[29vZYjwdoV{e2mwZzDOMZRmem2rbnHsJGhqey22YXfn[YQhcHWvYX6gdFg2[SC3c3nu[{BNNWGucHjhMZBpd3OyaHH0bYR6dGmwb4PpeI9tKHO3YoP0doF1\SCkeTDUUGMh[mG|ZXSgdIhwe3Cqb4KgbY1i\2mwZzygTWM2OD1yLkWg{txO NUC4fIFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
HEK293 cells NI\ZdZRHfW6ldHnvckBie3OjeR?= NH3LOGEyNjViaB?= MkPHSIl{eGyjY3Xt[Y51KG:oIGuzTH1NW0RiZoLvcUBpfW2jbjC1THQ3KHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNU42KGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\w>? M1nMdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUO3NVU{Lz5{MkWzO|E2OzxxYU6=
human H1299 cells MlP5SpVv[3Srb36gZZN{[Xl? NHnrSowxNjFvM{Cg{txO M3LuTlI1KGh? MWTJcoR2[3Srb36gc4YhUk6NLX3l[IlifGWmIFPIU3Ah\XiycnXzd4lwdiCrbjDoeY1idiCKMUK5PUBk\WyuczDheEAxNjFidH:gN|AhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NH\Bb3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[yNlA3QSd-MkK2NlIxPjl:L3G+
human H1299 cells Mn;VSpVv[3Srb36gZZN{[Xl? MYSwMlEuOzBizszN NEXOcmUzPCCq M2DYSGlv\HWldHnvckBw\iCGUkWg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
human H1299 cells MnnYSpVv[3Srb36gZZN{[Xl? NGrGXHYxNjFvM{Cg{txO NYPXXG9DOjRiaB?= M2HtdWRwf25icnXneYxifGmxbjDv[kBkUUGSMjDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{KGmwIIDy[ZNmdmOnIH;mJFExOCC3Zz;tcEBVWkGLTDDhcoQhWEl|SzDpcohq[mm2b4KgUHkzQTRyMEK= MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells NVL4V4lXTnWwY4Tpc44h[XO|YYm= MYGwMlEuOzBizszN MUCyOEBp MkfwSI94diC{ZXf1cIF1cW:wIH;mJINKSVB{IHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
MDA-MB-231 cells NFLiZWRE\WyuIHnueoF{cW:wIHHzd4F6 NV;aSm9GOjRiaB?= MVLJcohq[mm2aX;uJI9nKGWyaYTo[Yxq[WxiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIH;mJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNicILlMYlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHPlcIwhcW64YYPpc44h[XO|YYmsJGlEPTB;MD6zPEDPxE1w NFm3THg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwOFExQCd-MkK4NFQyODh:L3G+
human LNCAP cells NIH5XXFHfW6ldHnvckBie3OjeR?= M{PheFAvOS1|MDFOwG0> MXiyOEBp MV7Ec5dvemWpdXzheIlwdiCxZjDzeZJ3cX[rbjDlfJBz\XO|aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M33UUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN|E3Lz5{MkizNlMyPjxxYU6=
human LNCAP cells MmXvSpVv[3Srb36gZZN{[Xl? M1jGNVAvOS1|MDFOwG0> NGLnN2Q{OCCvaX6= MljqTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> M3\BWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN|E3Lz5{MkizNlMyPjxxYU6=
human PC3 cells MYXGeY5kfGmxbjDhd5NigQ>? M4XaT|UxKM7:TR?= MoL4PEBp NHe5TIhKdmS3Y4Tpc44hd2ZicEKxJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCqdX3hckBRSzNiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjC4JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s M4TQXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUm4OFczLz5{Mkm5PFQ4OjxxYU6=
human BT474 cell MkfmVJJwdGmoZYLheIlwdiCjc4PhfS=> NILYOJA4OiCq MmnuTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch|ryPLh?= NHzFRWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNFAxPSd-MkO0NVAxODV:L3G+
human PC3 cell MUTQdo9tcW[ncnH0bY9vKGG|c3H5 MVO3NkBp NFHq[FFKdmirYnn0bY9vKG:oIHj1cYFvKFCFMzDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrczygTWM2OD1zMj6xJO69VS5? M4XSZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEGwNFA2Lz5{M{SxNFAxPTxxYU6=
human PC3 cells MYfGeY5kfGmxbjDhd5NigQ>? NXnhTHh1OzBibXnu M4rLSWlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBRSzNiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gRWtVKHCqb4PwbI9zgWyjdHnvckBifCC|ZYLpcoUhPDd|IHHmeIVzKDNyIH3pcpMh[nliRVzJV2EtKEmFNUC9NU4{|ryPLh?= M4PiVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEGwNFA2Lz5{M{SxNFAxPTxxYU6=
human MGC803 cells M3;ZNGZ2dmO2aX;uJIF{e2G7 MnPVNlUh|ryP M3\IZlQ5KGh? NWjnb5NHS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUeFOECzJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJIF1KDJ3IIXNJIFnfGW{IES4JIhzeyC3c3nu[{Bxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIFnfGW{IES4JIhzeyCkeTDmcI94KGO7dH;t[ZRmeiC{ZXzheIl3\SC2bzDjc451em:u MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzOUi2PUc,OjRzMUm4Olk9N2F-
mouse RAW264.7 cells MULGeY5kfGmxbjDhd5NigQ>? NIPE[4UzPSEQvF2= M{TpfVIxKGh? M3TWdGlvcGmkaYTpc44hd2ZiUFmzT{9CU1RiaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCrTl;TJJBzd3SnaX6g[ZhxemW|c3nvckBifCB{NTFOwG0h[W[2ZYKgNlAhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NVX2foxoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVk3OTZpPkK0Nlk6PjF4PD;hQi=>
human A549 cells NUfPN|FCWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3n0VVczKGh? NHu2O4tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OEKuN|Ih|ryPLh?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7M{e4O{c,OjV4OUO3PFc9N2F-
human HuH7 cells MnPJVJJwdGmoZYLheIlwdiCjc4PhfS=> NFzWcnM4OiCq MlnuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKdVi3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTZ5LkG4JO69VS5? M4W4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmzO|g4Lz5{NU[5N|c5PzxxYU6=
human HCT116 cells NUnlTnR6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NFy2VHg4OiCq M{\rNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWxMlgzKM7:TT6= NHi1WGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HL60 cells NGHmUoFRem:uaX\ldoF1cW:wIHHzd4F6 MWO3NkBp M17KfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zOD60N{DPxE1w NFzaZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
Sf9 cells M{npN2Z2dmO2aX;uJIF{e2G7 NUHhcGJnUW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJIh2dWGwIFPLNkBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxKD1iNj65JO69VS5? NIXEVoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEm5PFM2OSd-MUC5PVg{PTF:L3G+
HeLa cells MXLGeY5kfGmxbjDhd5NigQ>? M1TVVmlvKH[rdILvJIlvcGmkaYTpc44hd2ZiRF7BMYRmeGWwZHXueEBxem:2ZXnuJItqdmG|ZTjEUmEuWEtrIH\yc40hUGWOYTCobJVu[W5iY3HyZ4lvd22jKTDj[Yxtey5uIFnDOVAhRSBzLkSg{txONg>? M{fnb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN|M6Lz5zMkm0NVM{QTxxYU6=
HeLa cells NYiw[oQ5TnWwY4Tpc44h[XO|YYm= NX\RVWYzUW6qaXLpeIlwdiCxZjDEUmEh\GWyZX7k[Y51KHC{b4TlbY4hc2mwYYPlJIl{d2yjdHXkJIZzd21iSHXMZUBk\WyuczygTWM2OCB;IEGuOUDPxE1w M1XtWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
Sf21 cells NWDzcXF5TnWwY4Tpc44h[XO|YYm= MXfJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{1qdm[nY4Tl[EBU\jJzIHPlcIx{NCCLQ{WwJF0hOC57IN88UU4> NU\Md4ZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
Sf21 cells NVnWT4MzTnWwY4Tpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGKxdnnu[UBz\WOxbXLpcoFvfCCSSUPL[4FudWFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoMkGgZ4VtdHNuIFnDOVAhRSB5IN88UU4> NUTGdHdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
HeLa cells MoPGSpVv[3Srb36gZZN{[Xl? NVLB[XlNSWO2aY\peJkh[XRiUFmzT{BqdiCqdX3hckBJ\UyjIHPlcIx{KGK7IFXMTXNCNCCHQ{WwJF0hOS53IN88UU4> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB7MkOyN{c,OjByOUKzNlM9N2F-
Sf21 cells M2raSWZ2dmO2aX;uJIF{e2G7 NFPReYpKdmirYnn0bY9vKG:oIGDJN2tl\Wy2YTDlfJBz\XO|ZXSgbY4h[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NEA:KDBwNUeg{txONg>? NYnkXlVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
Sf21 cells M{XXNWZ2dmO2aX;uJIF{e2G7 NGTSVXVKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCSSUPLZoV1[SCneIDy[ZN{\WRiaX6gV4YzOSClZXzsd{Bkdy2neIDy[ZN{cW6pIF6teIVzdWmwYXygTIl{NXSjZ3fl[EBpfW2jbjDwPFViKHW|aX7nJGwu[WyyaHGtdIhwe3CqYYTp[JltcW6xc3n0c4whe3Wkc4TyZZRmKGK7IGTMR{Bj[XOnZDDwbI9{eGixcjDpcYFocW6pLDDJR|UxKD1iMD65O{DPxE1w Mn63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3MkC2N|AoRjJ{NUKwOlMxRC:jPh?=
HL60 cells M4HGVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M{Xr[lMh\GG7cx?= MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF2IN88UU4> NH3oRZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U937 cells NI\uSXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVGzJIRigXN? MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV7M{egZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF2IN88UU4> Moi1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NEWxNVAoRjJ4OUS1NVExRC:jPh?=
Jurkat cells MnfoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NGO4eW0{KGSjeYO= NWHxWVBsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgN{Bl[Xm|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFIzKM7:TT6= NUTzc3lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
K562 cells M4S2V2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3S4UVMh\GG7cx?= M4TrfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iM{ig{txONg>? NGLpU|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U266 cells M17uN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmLqN{Bl[Xm| NILRbHpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGWyOlYh[2WubIOgcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OCB;IES2JO69VS5? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
MDA-MB-231 cells MX;BcpRqdWmpcnH0c5J6KGG|c3H5 Mm\SNlQhcHK| MYLBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGGpYXnud5QhTUeIIHnu[JVk\WRiY3jlcY91[XirczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIDy[Ylv[3WkYYTl[EBnd3JiMkSgbJJ{KG[xbHzve4VlKGK7IFXHSkBi\GSrdHnvckBnd3JiMz61JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxKD1iMD6zPEDPxE1w MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV7OEKzO{c,Ojd3OUiyN|c9N2F-
MDA-MB-231 cells NILFcI1CdnSraX72ZZNqfmViYYPzZZk> M3;kXFMvPSCqcoO= NWToUHB[SW62aXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDj[YxtKGmwdnHzbY9vKGGodHXyJFMvPSCqcoOsJGlEPTBiPTCwMlM5KM7:TT6= NEfES5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECwPVUzOSd-MkiwNFk2OjF:L3G+
HEK293T cells M1:ydmZ2dmO2aX;uJIF{e2G7 NGn2SZgyKGi{ MX7Jcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tj\XSjIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKGi{IHL5JGxENU2VL13TJIFv[Wy7c3nzMEBKSzVyIE2gNE41OiEQvF2u Mlu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
HEK293T cells MVHGeY5kfGmxbjDhd5NigQ>? NGrCUVAyKGi{ NGrFWWRKdmirYnn0bY9vKG:oIHntcY9jcWyrenXkJG4uVFl{OUSwNFIh[mWjZDDibY5lcW6pIITvJHBKO0umZXz0ZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIlv[3WkYYTl[EBnd3JiMTDodkBjgSCOQz3NV{9OWyCjbnHsfZNqeyxiSVO1NEA:KDFwNUOg{txONg>? NVrzSVF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
HEK293T cells Mnj2SpVv[3Srb36gZZN{[Xl? NULNdYpUOSCqch?= M1HqNGlvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2GucHjhJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiHS{K5N3Qh[2WubIOgbY5kfWKjdHXkJIZweiBzIHjyJIJ6KEyFLV3TM21UKGGwYXz5d4l{NCCLQ{WwJF0hOi5|NzFOwG0v MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
MDA-MB-231 cells NIXB[G1HfW6ldHnvckBie3OjeR?= MkW3TY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDpcpZie2mxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOzhizszNMi=> M1[yeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{CyOFAyLz5{OEOwNlQxOTxxYU6=
MCF7 cells NWnMWGVFTnWwY4Tpc44h[XO|YYm= NUnmSGhjOTBidV2= MlLYNUBpeg>? NV23V4oxUW6qaXLpeIlwdiCxZjDJS2YyWiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVE3OSC{ZYPp[JVmKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOSCqcjDifUBJd2WlaIP0JFM{OjV6IIP0ZYlvcW6pIHLhd4VlKGmvbYXuc4hqe3SxY3jlcYlk[WxiYX7hcJl{cXN? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
SKOV3 cells MnPjSpVv[3Srb36gZZN{[Xl? NFq2XZUzOCC3TR?= MlHvNlQhcHK| MnvZTY5pcWKrdHnvckBw\iCERF7GMYlv\HWlZXSgbY53[XOrb36gbY4hcHWvYX6gV2tQXjNiY3XscJMh[XRiMkCgeW0h[W[2ZYKgNlQhcHK|IHnuJIJ6KG2jdILp[4VtKGmwdnHzbY9vKGG|c3H5 MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF{MkS4OEc,OjlzMkK0PFQ9N2F-
SKOV3 cells NHvMSYVCdnSrbXnndoF1d3K7IHHzd4F6 NXnTcJA{OjBidV2= NITFV24zPCCqcoO= NGr4SplCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCERF7GMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25iYYSgNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KHOlcnH0Z4ghf2:3bnSgbIVidGmwZzDhd5NigQ>? MnnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMkK0PFQoRjJ7MUKyOFg1RC:jPh?=
NB1643 cells MYXxTHRUKGG|c3H5 MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NXzyTZRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 cells M1HwU5FJXFNiYYPzZZk> MmH3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 cells M1z0eJFJXFNiYYPzZZk> NXvMdoFQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> NF;5d|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC cells MW\xTHRUKGG|c3H5 Mn\EdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= NFq3U3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
J774 cells MVrBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NUDXRWVMOjRiaILz MYHBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIFq3O|Qh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFzQV{1qdmS3Y3XkJG1EWDFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUCgQUA{NjdizszNMi=> M1TVbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells M13zN2FvfGmrbn\sZY1u[XSxcomgZZN{[Xl? M2rmclI1KGi{cx?= M1W1dWFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhUUx4IHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPS5zIN88UU4> M1\XSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells Mn3NRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? NHTySGQzPCCqcoO= NE\6WmlCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJGo4PzRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGxRWy2rbnT1Z4VlKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIFnfGW{IEK0JIhzeyCkeTDHdolme3NiYYPzZZktKEmFNUCgQUA5NjlizszNMi=> MmTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5Mk[2PFAoRjJ7N{K2OlgxRC:jPh?=
J774 cells MXvGeY5kfGmxbjDhd5NigQ>? NFSycVkyOCC3TR?= NWHvWmppPCCqcoO= Mne5TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDtc5V{\SCMN{e0JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCOUGOtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{BifCBzMDD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
E-cadherin / p-Akt / Akt; 

PubMed: 29731993     


Immunoblot analysis of E-cadherin, P-AKT, and AKT in SNU-C5/5-FU cells treated with LY294002 (20 μM).

beta-catenin / p-GSK3β / Cyclin D1; 

PubMed: 29731993     


Immunoblot analysis of P-AKT, AKT, β-catenin, P-GSK-3β, GSK-3β, and cyclin D1 in SNU-C5/5-FU cells treated with LY294002 (20 μM).

Bcl-xl / Bax / caspase3 / cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of LY294002 for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin; 

PubMed: 23251002     


HT29, Colo205, and RKO cells were treated for 2 h with PLX4720, LY294002 or their combination at indicated concentrations. Cell lysates were subjected to western blot analysis with antibodies against phosphorylated or total forms of AKT or ERK1/2, and antibodies against p-P70S6K, pGSK3β or vinculin.

pPKB-S473; 

PubMed: 20649566     


Typical Western blot showing that basal pPKB-S473 was reduced by increasing concentrations of LY294002 (upper panel). Pre-incubating 10 µM of the MEK-1/2 inhibitor U0126 induced pPKB–S473 levels which were reduced when rising concentrations of LY294002 were added. A full suppression of pPKB–S473 below the detection limit was seen at 30 µM PI3K inhibitor (10 µM U0126 + 30 µM LY294002). β-Actin immunoreaction served as loading control.

29731993 25344912 23251002 20649566
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of LY294002 on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
Immunofluorescence
α-SMA / CD31; 

PubMed: 27671604     


Immunofluorescence analysis for the expression levels of CD31 and α-SMA in Control, LY294002, As2O3 and As2O3 + LY294002 groups. Scale bar = 30 μm. (in HAECs).

E-cadherin / beta-catenin; 

PubMed: 29731993     


The localization of E-cadherin and β-catenin were confirmed by confocal microscopy. Scale bars, 20 μm.

COX-2 / p-NFκB; 

PubMed: 29731993     


The localization of Cox-2 and P-NF-κB was confirmed by confocal microscopy. Scale bars, 20 μm.

FOXO3a; 

PubMed: 18388194     


C2C12 cells were plated into two-well chamber sliders for 24 h and then treated with 20 μm LY294002 or the same amount of vehicle (ethanol) for 16 h. Cells were fixed and FOXO3a was stained. LY294002 treatment activates FOXO3a and leads its translocation into the nucleus.

27671604 29731993 18388194
ELISA
IL-10 / IL-1β / TNFα / IL-6; 

PubMed: 22208359     


Microglial cells were pre-treated with LY294002 for 1 h and then stimulated with LPS (100 ng/ml) or PIC (10 μg/ml) for 16 h. ELISA were performed. All values were normalized to those obtained in cultures stimulated with LPS or PIC without LY294002 (= 1). At least 3 cases were analyzed for each experiment, and statistics were performed using t-test comparing values with vs. without LY294002.

22208359
In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol

Kinase Assay:

[4]
- Collapse

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:

[2]
- Collapse
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing. 		3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3
CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286
Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02337309 Terminated Drug: SF1126 Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|SignalRX Pharmaceuticals Inc.|University of Southern California July 9 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • Answer:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • Question 2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

selleck catalog

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147) New

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

  • Wortmannin (KY 12420)

    Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

  • Dactolisib (BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

  • Buparlisib (BKM120)

    Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID